发明名称 Guaifenesin sustained release formulation and tablets
摘要 The invention relates to a novel pharmaceutical sustained release formulation of guaifenesin. The formulation may comprise a hydrophilic polymer, preferably a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably an acrylic resin, in a ratio range of about one-to-one (1:1) to about six-to-one (6:1), more preferably a range of about three-to-two (3:2) to about four-to-one (4:1), and most preferably about two-to-one (2:1), by weight. This formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release guaifenesin tablet which has two portion: the first portion comprises an immediate release formulation of guaifenesin and the second portion comprises a sustained release formulation of guaifenesin as described above. This two portion, or bi-layer, tablet has a maximum serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.
申请公布号 US6372252(B1) 申请公布日期 2002.04.16
申请号 US20000559542 申请日期 2000.04.28
申请人 ADAMS LABORATORIES, INC. 发明人 BLUME RALPH W.;DAVIS ROBERT D.;KEYSER DONALD JEFFREY
分类号 A61K9/20;A61K9/22;A61K9/24;A61K9/50;A61K9/52;A61K9/58;A61K31/09;A61K31/137;A61K31/485;A61K31/495;A61K47/04;A61K47/08;A61K47/12;A61K47/18;A61K47/20;A61K47/26;A61K47/30;A61K47/32;A61K47/34;A61K47/36;A61K47/38;A61K47/44;A61P11/10;(IPC1-7):A61K9/20;A61K9/00;A61K9/28 主分类号 A61K9/20
代理机构 代理人
主权项
地址